ALKBH3 and melanoma: Moreover, both histone lactylation inhibitors (oxamate and 2-DG) and LDHA/B inhibition have resulted in a dramatic decreased histone lactylation levels in the promoter region of ALKBH3 (Figure 3F), which subsequently abrogates the RNA (Figure 3G) and protein levels (Figure 3H-J) of ALKBH3 in all tested melanoma cells.